Aleksandra Semeniuk-Wojtaś1, Arkadiusz Lubas2, Rafał Stec3, Tomasz Syryło4, Stanisław Niemczyk2, Cezary Szczylik5. 1. Department of Oncology, Military Institute of Medicine, Warsaw, Poland. Electronic address: asemeniuk@wim.mil.pl. 2. Department of Nephrology, Military Institute of Medicine, Warsaw, Poland. 3. Department of Oncology, Military Institute of Medicine, Warsaw, Poland. 4. Department of Urology, Military Institute of Medicine, Warsaw, Poland. 5. Medical University in Warsaw, Warsaw, Poland.
Abstract
BACKGROUND: Inflammation plays a crucial role in cancer development. In this study, we evaluate the prognostic values of systemic inflammation markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) for the progression-free survival and overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. MATERIALS AND METHODS: PubMed and the Cochrane Library databases were searched for published studies on the effect of NLR, PLR, and CRP in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. RESULTS: In the meta-analysis, NLR (hazard ratio [HR], 2.01; 95% confidence interval [CI], 1.27-3.18; P = .003) and PLR (HR, 6.96; 95% CI, 5.04-9.62; P < .001) had a significant influence on progression-free survival, whereas all considered proinflammatory markers had a significant impact on overall survival: NLR (HR, 2.14; 95% CI, 1.67-2.73; P < .001), PLR (HR, 14.67; 95% CI, 11.10-19.57; P < .001), and CRP (HR, 1.96; 95% CI, 1.26-3.05; P = .003). CONCLUSIONS: Inflammation markers such as NLR, PLR, and CRP are predictors of clinical outcome and could provide additional information to individualize treatment.
BACKGROUND:Inflammation plays a crucial role in cancer development. In this study, we evaluate the prognostic values of systemic inflammation markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) for the progression-free survival and overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. MATERIALS AND METHODS: PubMed and the Cochrane Library databases were searched for published studies on the effect of NLR, PLR, and CRP in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. RESULTS: In the meta-analysis, NLR (hazard ratio [HR], 2.01; 95% confidence interval [CI], 1.27-3.18; P = .003) and PLR (HR, 6.96; 95% CI, 5.04-9.62; P < .001) had a significant influence on progression-free survival, whereas all considered proinflammatory markers had a significant impact on overall survival: NLR (HR, 2.14; 95% CI, 1.67-2.73; P < .001), PLR (HR, 14.67; 95% CI, 11.10-19.57; P < .001), and CRP (HR, 1.96; 95% CI, 1.26-3.05; P = .003). CONCLUSIONS:Inflammation markers such as NLR, PLR, and CRP are predictors of clinical outcome and could provide additional information to individualize treatment.
Authors: Tae Woo Kim; Jung Hwan Lee; Kang Hee Shim; Seol Ho Choo; Jong Bo Choi; Hyun Soo Ahn; Se Joong Kim; Sun Il Kim Journal: Investig Clin Urol Date: 2018-11-23
Authors: Anup Patel; Alain Ravaud; Robert J Motzer; Allan J Pantuck; Michael Staehler; Bernard Escudier; Jean-François Martini; Mariajose Lechuga; Xun Lin; Daniel J George Journal: Clin Cancer Res Date: 2020-06-16 Impact factor: 12.531